In the Clinic
![Piro Lito, Bob Li, and Neal Rosen in the lab](https://www.mskcc.org/sites/default/files/styles/width_200/public/node/209119/main_image/msk_200917_036-1200x800.jpg)
Promising Results from the First-Ever Trial of a Drug that Blocks Cancer Gene KRAS
The drug, sotorasib, is targeted against a cancer-causing protein that has long been considered an “undruggable” target.
In the Lab
![Scott Lowe and Neal Rosen](https://www.mskcc.org/sites/default/files/styles/width_200/public/node/128422/3x2/rose_lowe_3x2.jpg)
Knocking Out KRAS-Mutant Cancers with a One-Two Punch
A new approach aims to combine two existing targeted therapy drugs to attack lung cancer and pancreatic cancer with mutations in the hard-to-target gene KRAS.
In the Lab
![Colored x-ray of lung cancer](https://www.mskcc.org/sites/default/files/styles/width_200/public/node/118888/3x2/xray-lung-cancer.jpg)
New Lung Cancer Therapy May Target Previously Untreatable Tumors
Researchers are developing uses for a drug that could benefit many people with lung cancer.
In the Clinic
![Memorial Sloan Kettering medical oncologist Andrea Cercek](https://www.mskcc.org/sites/default/files/styles/width_200/public/node/195262/main_image/190306-km-msk-cercek-5-1200x800.jpg)
FDA Approval Gives Hope to Some People with Advanced Colorectal Cancer
A new treatment is approved for an especially aggressive kind of colorectal cancer.
In the Lab
![MSK investigators Joan Massagué and Anna Obenauf](https://www.mskcc.org/sites/default/files/styles/width_200/public/node/39567/image/massague-obenauf.jpg)
Outsmarting Cancer’s Survival Skills
A new study led by MSK investigators reveals how some cancer cells become resistant to targeted treatment and suggests what might be done to stop that from happening.
Profile
![Pictured: David Solit](https://www.mskcc.org/sites/default/files/styles/width_200/public/node/30106/image/david-solit.jpg)
At Work: Physician-Scientist David Solit
David Solit, Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, discusses how working with cancer patients drives him to develop more-effective, personalized cancer treatments.
Honors
![Five Memorial Sloan Kettering researchers have been named to Stand Up To Cancer's new Melanoma "Dream Team."](https://www.mskcc.org/sites/default/files/styles/width_200/public/node/12232/image/su2c-logo-white.jpg)
Memorial Sloan Kettering Researchers Appointed to Stand Up To Cancer Melanoma “Dream Team”
Five Memorial Sloan Kettering scientists have been appointed to a new research team dedicated to identifying targets for therapies to treat a certain form of melanoma.